Glycan Therapeutics, LLC

Contact: Jim Peterson
Location: **Chapel Hill, NC**
Email: jimpeterson@glycantherapeutics.com
Tel: **919-302-6489**
Website: http://www.glycantherapeutics.coom

Company Profile

Industry Sector: Biotechnology

Company Overview: Glycan Therapeutics was founded in 2013 and is located in Chapel Hill, NC. The company is a spin out from UNC Chapel Hill. Glycan is a pioneer in the synthesis of structurally defined heparan sulfate and heparin oligosaccharides for glycobiology researchers using a new patented chemoenzymatic technology.

Target Market(s):
- Academic and Industry research laboratories.
-Anticoagulants, cancer, anti-infectives and diagnostic markers.

Key Value Drivers

Technology*: A platform technology using chemoenzymatic synthesis of heparin and heparin like compounds. It is very cost efficient by significantly reducing the steps required compared to chemical synthesis.

Competitive Advantage: We can produce high purity products that are cheaper than chemical synthetic methods suitable for research and drug development. The process is versatile and scalable. .

Plan & Strategy:
-Sell oligosaccharide .library compounds and perform custom synthesis of heparan sulfate compounds.
-Develop synthetic heparin and other biotherapeutics based on heparan sulfates.

Management

Leadership:
Jian Liu, Ph.D.- Founder and Chief Scientific Officer
Jian is a Distinguished Professor at UNC-CH and has spent more than 25 years working with heparin. He is the inventor of the enzyme-based method to prepare heparan sulfate compounds.

Jim Peterson, Ph.D, MBA- Chief Operating Officer
Jim started his career as Group Leader at Sterling Drug and has an additional 25 years experience in research administration and research consulting and business consulting.

Product Pipeline

1. Pipeline One: The company offers a catalogue of 24 homogeneous heparan sulfate oligosaccharides with 39 additional compounds in June 2016.

2. Pipeline Two: Glycan can synthesize heparan sulfate oligosaccharides with unprecedented structural complexity. and also offers custom synthesis of oligosaccharides with different sizes, sulfation, and purity up to 18-mers.

3. Pipeline Three: Develop carbohydrate based medicines including synthetic Heparin, cancer, anti-infectives and diagnostic markers.